Many investors pay attention to mid-cap stocks because they have established business models and expansive market ...
We are proud to announce that the 57th season of the Nordson-Academic Challenge will return in 2026, beginning Jan. 3, 2026.
StockStory.org on MSN
3 industrials stocks we steer clear of
Whether you see them or not, industrials businesses play a crucial part in our daily activities. But their prominence also ...
24/7 Wall St. on MSN
The 3 Best Dividend Aristocrats to Buy in 2026
Investing in Dividend Aristocrats can anchor your portfolio by providing solid dividend growth from proven, successful ...
Zacks Investment Research on MSN
Strength in medical & fluid solutions unit drives Nordson: Can it sustain?
Nordson Corporation NDSN is witnessing solid momentum in the Medical and Fluid Solutions segment, organic sales from which ...
Nordson Corporation ( NASDAQ:NDSN ) saw significant share price movement during recent months on the NASDAQGS, ...
Dividend Kings offer durable income and compounding power. Discover why Nordson stands out as an under-the-radar stock built ...
Nordson Corp (NASDAQ:NDSN) fell by 5.43% to $236.01 in after-hours on Wednesday as the company revenue guidance for the fiscal year 2025 was below analyst expectations. However, the technical analysis ...
Newest Industry 4.0 innovation from Nordson EFD takes top honors in the Automation and IIOT category EAST PROVIDENCE, R.I.--(BUSINESS WIRE)--Nordson EFD, a Nordson company (NASDAQ: NDSN), announced ...
“This divestiture allows Nordson MEDICAL to focus on its higher value growth opportunities within our $800 million medical and fluid solutions segment. This includes our growing portfolio of ...
Nordson is fundamentally sound but heavily reliant on acquisitions for growth. Future returns may be lower unless Nordson improves capital efficiency or executes more cost-effective acquisitions. The ...
Westlake-based Nordson Corp. (Nasdaq: NDSN) has agreed to acquire Atrion Corp. (Nasdaq: ATRI), a maker of medical infusion fluid delivery and cardiovascular products, for $460 per share in cash, or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results